Document is current

Article History

Received: 31 August 2022

Accepted: 2 December 2022

First Online: 20 December 2022

Declarations

:

: Ethical approval for this study was provided by Ethikkommission der Ärztekammer des Saarlandes, Germany, during the ethics approval meeting on Feb 16, 2017, with final approval on April 18, 2017. Ethical approval was also provided by National Medical Ethics Committee Komisija republike Slovenije za medicinsko etiko, Slovenia on June 6, 2019. Written informed consent was obtained from the patient or the patient’s representative, as appropriate. The study was done in accordance with International Conference on Harmonisation Good Clinical Practice (ICH-GCP) standards and the Declaration of Helsinki.

: Not applicable.

: AM reports consultancy fees from Sedana Medical. TV reports grant support from B Braun. UG reports lecture fees from MT Monitor Technik and Getinge and reimbursement of clinical study expenses from Bayer Healthcare. TB reports personal lecture fees from Sedana Medical and Vyaire and institutional funding from Löwenstein Medical. PK reports personal fees and travel costs from Sedana Medical. MD reports lecture fees and travel costs from Cytosorbents Europe. PS reports employment by Sedana Medical and shareholding in Sedana Medical. All other authors declare no competing interests.